ERBB2 and breast cancer: In a study of immunomodulation of neu-expressing Turin-Bologna breast cancer tumors, AAV5-neu or AAV6-neu expression increased the survival (80% versus 100%, up to day 300) of the animal model by inducing long-term immunity against the tumor.27